JP2016506916A5 - - Google Patents

Download PDF

Info

Publication number
JP2016506916A5
JP2016506916A5 JP2015553788A JP2015553788A JP2016506916A5 JP 2016506916 A5 JP2016506916 A5 JP 2016506916A5 JP 2015553788 A JP2015553788 A JP 2015553788A JP 2015553788 A JP2015553788 A JP 2015553788A JP 2016506916 A5 JP2016506916 A5 JP 2016506916A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
cycloalkyl
group
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015553788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506916A (ja
JP6347793B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/011571 external-priority patent/WO2014113413A1/en
Publication of JP2016506916A publication Critical patent/JP2016506916A/ja
Publication of JP2016506916A5 publication Critical patent/JP2016506916A5/ja
Application granted granted Critical
Publication of JP6347793B2 publication Critical patent/JP6347793B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015553788A 2013-01-16 2014-01-15 Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法 Active JP6347793B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361753066P 2013-01-16 2013-01-16
US61/753,066 2013-01-16
PCT/US2014/011571 WO2014113413A1 (en) 2013-01-16 2014-01-15 Bcl-2bcl-xl inhibitors and therapeutic methods using the same

Publications (3)

Publication Number Publication Date
JP2016506916A JP2016506916A (ja) 2016-03-07
JP2016506916A5 true JP2016506916A5 (cg-RX-API-DMAC7.html) 2017-01-26
JP6347793B2 JP6347793B2 (ja) 2018-06-27

Family

ID=51165292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015553788A Active JP6347793B2 (ja) 2013-01-16 2014-01-15 Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法

Country Status (13)

Country Link
US (2) US9096625B2 (cg-RX-API-DMAC7.html)
EP (2) EP3689886A1 (cg-RX-API-DMAC7.html)
JP (1) JP6347793B2 (cg-RX-API-DMAC7.html)
KR (2) KR102318204B1 (cg-RX-API-DMAC7.html)
CN (3) CN105246882A (cg-RX-API-DMAC7.html)
AU (1) AU2014207716B2 (cg-RX-API-DMAC7.html)
CA (1) CA2897055C (cg-RX-API-DMAC7.html)
ES (1) ES2819232T3 (cg-RX-API-DMAC7.html)
HK (1) HK1219734A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ709635A (cg-RX-API-DMAC7.html)
SG (1) SG11201505525UA (cg-RX-API-DMAC7.html)
WO (1) WO2014113413A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201504902B (cg-RX-API-DMAC7.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689886A1 (en) * 2013-01-16 2020-08-05 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
IL286427B2 (en) 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
EP3139942B1 (en) 2014-05-05 2019-12-18 Bioventures, Llc COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
WO2016014625A1 (en) 2014-07-22 2016-01-28 Board Of Trustees Of The University Of Arkansas Compositions and methods for selectively depleting senescent cells
WO2016127135A1 (en) * 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditons
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
WO2017101851A1 (en) * 2015-12-18 2017-06-22 Unity Biotechnology, Inc. Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
CA3103604C (en) 2016-03-28 2023-09-26 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
CN109152933B (zh) * 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
CN106177955B (zh) * 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
WO2018098534A1 (en) * 2016-12-02 2018-06-07 Garvan Institute Of Medical Research Methods of treating cancer and reagents thereof
US20200354336A9 (en) * 2017-08-11 2020-11-12 Unity Biotechnology, Inc. Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
WO2019033122A1 (en) * 2017-08-11 2019-02-14 Unity Biotechnology, Inc. TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
WO2019033119A1 (en) * 2017-08-11 2019-02-14 Unity Biotechnology, Inc. TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
US10588916B2 (en) 2017-10-31 2020-03-17 Unity Biotechnology, Inc. Technology to inhibit vascular changes that lead to vision loss in the eye
AU2018357829B2 (en) 2017-12-30 2019-09-26 Unity Biotechnology, Inc. Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
KR20200108301A (ko) 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
ES3041854T3 (en) * 2018-01-22 2025-11-17 Bioventures Llc Bcl-2 proteins degraders for cancer treatment
SG11202009933WA (en) 2018-04-29 2020-11-27 Beigene Ltd Bcl-2 INHIBITORS
CN117866015A (zh) 2018-04-30 2024-04-12 联合生物科技公司 一种临床管理中使用的化合物及其用途
CA3056878C (en) 2018-04-30 2021-03-30 Unity Biotechnology Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
US10738042B2 (en) 2018-04-30 2020-08-11 Unity Biotechnology, Inc. Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof
US10717722B2 (en) 2018-06-13 2020-07-21 Unity Biotechnology, Inc. Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
BR112020018978A2 (pt) 2018-07-31 2021-03-02 Ascentage Pharma (Suzhou) Co., Ltd. produto de combinação que compreende um inibidor de bcl-2 e um inibidor de mdm2 e uso dos ditos inibidores na prevenção e/ou tratamento de câncer
US11554127B2 (en) 2018-07-31 2023-01-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
CA3095699A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
CN114522167A (zh) * 2018-07-31 2022-05-24 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
TW202019421A (zh) * 2018-07-31 2020-06-01 大陸商蘇州亞盛藥業有限公司 Bcl-2/Bcl-xL抑制劑與化療藥物的組合及其應用
US11491168B2 (en) 2018-07-31 2022-11-08 Ascentage Pharma (Suzhou) Co., Ltd. Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
US11872237B2 (en) * 2018-12-28 2024-01-16 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and preparation method thereof
EP3906235B1 (en) 2019-01-04 2023-03-15 Ascentage Pharma (Suzhou) Co., Ltd. Method for preparing sulfonamides drugs
TWI729662B (zh) * 2019-01-04 2021-06-01 大陸商蘇州亞盛藥業有限公司 一種磺胺類化合物及製備磺胺類化合物的製程
TWI770503B (zh) * 2019-05-13 2022-07-11 大陸商蘇州亞盛藥業有限公司 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
CN112168830B (zh) * 2019-07-02 2022-01-25 苏州亚盛药业有限公司 一种含有mTOR抑制剂的药物组合及其应用
US12370197B2 (en) * 2019-07-31 2025-07-29 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US20220372042A1 (en) 2019-10-03 2022-11-24 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
CN112707900B (zh) * 2019-10-24 2022-06-10 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
US12287338B2 (en) 2019-11-27 2025-04-29 Ascentage Pharma (Suzhou) Co., Ltd. Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
TWI777321B (zh) * 2019-12-04 2022-09-11 大陸商蘇州亞盛藥業有限公司 藥物組合及其用途
CN114786654A (zh) * 2019-12-11 2022-07-22 密执安大学评议会 用于全身递送Bcl-2和Bcl-xL拮抗剂的组合物和方法
CN113350281B (zh) * 2020-03-02 2023-08-15 苏州亚盛药业有限公司 载药聚合物胶束及其制剂和制备方法
WO2021204060A1 (en) * 2020-04-10 2021-10-14 Ascentage Pharma (Suzhou) Co., Ltd. Combinations of bcl-2/bcl-xl inhibitors and related uses
IL296582A (en) 2020-04-15 2022-11-01 Beigene Ltd bcl-2 inhibitor
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
EP4175644A1 (en) 2020-07-06 2023-05-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
CN113929715A (zh) * 2020-07-13 2022-01-14 苏州亚盛药业有限公司 Bcl-2/Bcl-xL抑制剂化合物或其盐的结晶形式或无定形形式
WO2022022706A1 (en) * 2020-07-31 2022-02-03 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating lung diseases
KR20230145313A (ko) * 2020-11-10 2023-10-17 유니티 바이오테크놀로지, 인크. Bcl의 결정성 고체 메글루민 염 억제제 및 이의 제조 방법 및 이의 사용 방법
WO2022111647A1 (en) * 2020-11-27 2022-06-02 Ascentage Pharma (Suzhou) Co., Ltd. Formulation combination containing freeze-dried formulation and reconstituted solvent, preparation method and application thereof
WO2022120114A1 (en) 2020-12-04 2022-06-09 University Of Notre Dame Du Lac Method of encapsulating single cells utilizing an alternating current electrospray
CN117957018A (zh) 2021-08-02 2024-04-30 苏州亚盛药业有限公司 一种药物组合及其用途
EP4565236A1 (en) * 2022-08-02 2025-06-11 Beijing Neox Biotech Limited Bcl-xl degrading compounds
WO2024051741A1 (zh) * 2022-09-06 2024-03-14 西藏海思科制药有限公司 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用
EP4719408A1 (en) * 2023-05-30 2026-04-08 Ascentage Pharma (Suzhou) Co., Ltd. Bcl-2/bcl-xl protein degrader and use thereof
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
AU2005277223C1 (en) 2004-08-20 2009-05-21 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
EP1948614A2 (en) 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
JP5277168B2 (ja) * 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するｂｃｌインヒビター
PT2324008E (pt) 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inibidores da proteína quinase
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
EP2668180B1 (en) * 2011-01-25 2018-08-01 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
EP3689886A1 (en) * 2013-01-16 2020-08-05 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2016506916A5 (cg-RX-API-DMAC7.html)
JP2014507421A5 (cg-RX-API-DMAC7.html)
JP2019524883A5 (cg-RX-API-DMAC7.html)
JP2015532295A5 (cg-RX-API-DMAC7.html)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2024521706A5 (cg-RX-API-DMAC7.html)
JP2019529518A5 (cg-RX-API-DMAC7.html)
JP2017528498A5 (cg-RX-API-DMAC7.html)
JP2016040288A5 (cg-RX-API-DMAC7.html)
JP2019510832A5 (cg-RX-API-DMAC7.html)
JP2019516711A5 (cg-RX-API-DMAC7.html)
JP2016513737A5 (cg-RX-API-DMAC7.html)
JP2016536286A5 (cg-RX-API-DMAC7.html)
JP2015534578A5 (cg-RX-API-DMAC7.html)
JP2013507415A5 (cg-RX-API-DMAC7.html)
CN111918652A (zh) 用于治疗eb病毒阳性的癌症的趋化因子受体调节剂
JP2012506872A5 (cg-RX-API-DMAC7.html)
JP2019509986A (ja) トリプトライドのグルコース・コンジュゲート、その類縁体及び使用
RU2017112048A (ru) Синергистические комбинации ауристана
JP2016515628A5 (cg-RX-API-DMAC7.html)
JP2016531871A5 (cg-RX-API-DMAC7.html)
CN110248662A (zh) 一种治疗前列腺癌的组合、药物组合物及治疗方法
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов
JP2020534346A5 (cg-RX-API-DMAC7.html)
JP2015502926A5 (cg-RX-API-DMAC7.html)